Mylan has long been a champion for those living with or at risk for infection of HIV/AIDS. It’s part of our belief that access to high quality medicine is a right, not a privilege. In fact, today nearly half of all patients receiving treatment for HIV in the developing world depend on a Mylan product.
On Sept. 21 at the United Nations, Mylan announced its most recent step in the fight against the HIV epidemic. Together with a number of partners such as the Clinton Health Access Initiative (CHAI), UNAIDS, the Bill & Melinda Gates Foundation and the United Kingdom’s Department for International Development (DFID), Mylan entered into a unique public/private partnership to accelerate the availability of a next-generation antiretroviral treatment called TLD to patients in more than 90 low and middle income countries. As part of this alliance, Mylan has committed to selling this product (a combination tablet, taken once daily, of the three molecules Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate) to public-sector purchasers in countries such as South Africa and Kenya at about $75 per person per year. This initiative also supports one of the 2030 targets of the UN Sustainable Development Goal Number 3: ensure healthy lives and promote well-being for all at all ages of which Mylan is a proud supporter.
The development of TLD represents a significant achievement in the fight against HIV. When the first antiretrovirals were developed, it could take over a decade before low-cost generic versions were brought to developing countries. Then, when more effective and more tolerable molecules came out, they were significantly more expensive than their predecessors – straining health systems already struggling to put all their HIV-positive populations on treatment. With TLD, Mylan’s R&D team was able to develop a generic version just three years after the innovator’s launch. And Mylan’s product will in fact cost less than the previous standard of care.
Mylan is unique among western pharmaceutical companies in its commitment to providing millions of patients in developing countries with access to high quality medicine. We have invested more than $250 million to expand our ARV production capacity and we now manufacture more than 4 billion ARV tablets and capsules each year. Eight years ago, Mylan was the first company to launch a one pill, once-a-day regimen called TLE. In March of 2017, we were the first – and to date, the only – company to launch a lower-cost, reduced-dose version of this treatment. And in August 2017, we were the first company to launch TLD. Today, over half of our company’s active pharmaceutical ingredient (API) manufacturing capacity is devoted to antiretrovirals (ARVs).
According to UNAIDS, only just over half of the 37 million people living with HIV in the world are on treatment. So we still have a long way to go. Mylan will continue to be a partner in innovation and leadership – all in an effort to help end the AIDS epidemic and bring health and well-being to all people, everywhere. Learn more about Mylan’s work in the area of infectious disease.